Human Immunoglobulin E specific for Juniperus scopulorum pollen allergens (sIgE (Juniperus scopulorum))

Human IgE antibodies specific for Juniperus scopulorum pollen allergens are a specialized subset of the immunoglobulin E class that mediate allergic reactions to the Rocky Mountain Juniper. These antibodies are produced by B cells following sensitization to specific proteins in the pollen, most notably the major allergen Jun s 1, which is a pectate lyase (WHO/IUIS Allergen Nomenclature, 2023). In sensitized individuals, these IgE molecules are primarily found bound to the high-affinity FcεRI receptors on the surface of mast cells and basophils (Galli & Tsai, Nature Medicine, 2012). Upon subsequent exposure to Juniperus scopulorum pollen, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes, which lead to symptoms of hay fever and asthma (NIH, 2022). Therapeutic interventions include the use of the monoclonal antibody Omalizumab, which sequesters free IgE to prevent receptor binding, and allergen-specific immunotherapy, which aims to desensitize the immune system by modulating the IgE-mediated response (Cochrane Database, 2014). Understanding these specific antibodies is crucial for diagnosing and managing seasonal allergies in regions where Juniperus species are endemic (Journal of Allergy and Clinical Immunology, 2001).

Other names

Rocky Mountain Juniper-specific IgEAnti-Jun s IgEJuniperus scopulorum-specific IgEAnti-Jun s 1 IgE

Anti-IgE monoclonal antibodies bind to the Cε3 domain of the IgE molecule, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the release of inflammatory mediators.